Cipher Non Currrent Assets Other vs Total Current Assets Analysis
| CPH Stock | CAD 14.36 0.36 2.57% |
Cipher Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cipher Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cipher Pharmaceuticals is a good investment. Please check the relationship between Cipher Pharmaceuticals Non Currrent Assets Other and its Total Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cipher Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Non Currrent Assets Other vs Total Current Assets
Non Currrent Assets Other vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cipher Pharmaceuticals Non Currrent Assets Other account and Total Current Assets. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Cipher Pharmaceuticals' Non Currrent Assets Other and Total Current Assets is 0.41. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Cipher Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cipher Pharmaceuticals' Non Currrent Assets Other and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Cipher Pharmaceuticals are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Non Currrent Assets Other i.e., Cipher Pharmaceuticals' Non Currrent Assets Other and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.41 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Cipher Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cipher Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cipher Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Cipher Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 17th of December 2024, Discontinued Operations is likely to grow to about 196.8 K, though Tax Provision is likely to grow to (7.3 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 18.3M | 16.7M | 17.1M | 16.3M | Total Revenue | 21.9M | 20.7M | 21.2M | 18.1M |
Cipher Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Cipher Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cipher Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 46.5M | 44.3M | 51.7M | 73.8M | 86.0M | 46.4M | |
| Short Long Term Debt Total | 9.6M | 1.8M | 516K | 428K | 353K | 335.4K | |
| Other Current Liab | 4.5M | 5.2M | 450K | 257K | 295.6K | 280.8K | |
| Total Current Liabilities | 16.6M | 9.9M | 12.3M | 9.4M | 5.3M | 10.3M | |
| Total Stockholder Equity | 28.0M | 32.6M | 38.9M | 64.1M | 80.5M | 84.5M | |
| Property Plant And Equipment Net | 2.2M | 1.9M | 501K | 481K | 402K | 640.4K | |
| Current Deferred Revenue | 274K | 307K | 450K | 257K | 519K | 714.3K | |
| Net Debt | 3.2M | (7.3M) | (20.0M) | (28.4M) | (39.5M) | (37.5M) | |
| Retained Earnings | 13.9M | 18.4M | 25.2M | 50.5M | 66.3M | 69.6M | |
| Accounts Payable | 4.1M | 1.6M | 5.6M | 4.1M | 4.6M | 5.6M | |
| Cash | 6.3M | 9.1M | 20.5M | 28.8M | 39.8M | 41.8M | |
| Non Current Assets Total | 29.2M | 24.1M | 22.3M | 35.6M | 37.8M | 39.6M | |
| Non Currrent Assets Other | (28.3M) | (21.8M) | (19.9M) | (18.9M) | 19.9M | 20.9M | |
| Other Assets | 943K | 2.4M | 2.5M | 16.7M | 19.2M | 20.1M | |
| Cash And Short Term Investments | 6.3M | 9.1M | 20.5M | 28.8M | 39.8M | 41.8M | |
| Net Receivables | 8.9M | 9.2M | 6.7M | 6.8M | 5.1M | 8.6M | |
| Common Stock Shares Outstanding | 27.0M | 27.4M | 26.8M | 107.5M | 25.4M | 32.1M | |
| Liabilities And Stockholders Equity | 46.5M | 44.3M | 51.7M | 73.8M | 86.0M | 46.4M | |
| Non Current Liabilities Total | 1.8M | 1.7M | 460K | 327K | 259K | 246.1K | |
| Inventory | 1.0M | 892K | 1.7M | 2.2M | 3.0M | 3.1M | |
| Other Current Assets | 963.0K | 875K | 471K | 371K | 378K | 359.1K | |
| Other Stockholder Equity | 5.0M | 5.1M | 5.1M | 5.4M | 5.8M | 5.5M | |
| Total Liab | 18.4M | 11.6M | 12.8M | 9.7M | 5.5M | 5.2M | |
| Property Plant And Equipment Gross | 2.2M | 1.9M | 641K | 716K | 756K | 686.7K | |
| Total Current Assets | 17.2M | 20.1M | 29.3M | 38.2M | 48.3M | 27.9M | |
| Short Term Debt | 7.7M | 137K | 56K | 101K | 94K | 89.3K | |
| Intangible Assets | 10.4M | 4.2M | 3.6M | 2.8M | 1.8M | 1.7M | |
| Common Stock | 18.7M | 18.7M | 18.1M | 17.7M | 18.0M | 14.7M | |
| Other Liab | 1.2M | 19K | 8K | 5K | 4.5K | 4.3K | |
| Net Tangible Assets | 1.9M | 12.8M | 19.5M | 45.6M | 41.1M | 43.1M | |
| Property Plant Equipment | 2.2M | 1.9M | 501K | 481K | 553.2K | 788.2K | |
| Long Term Debt Total | 1.8M | 1.7M | 460K | 327K | 294.3K | 279.6K | |
| Capital Surpluse | 5.0M | 5.1M | 5.1M | 5.4M | 6.2M | 5.6M | |
| Net Invested Capital | 35.6M | 32.6M | 38.9M | 64.1M | 80.5M | 52.7M | |
| Net Working Capital | 615K | 10.2M | 17.0M | 28.8M | 43.0M | 45.2M |
Pair Trading with Cipher Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cipher Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cipher Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Cipher Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cipher Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cipher Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cipher Pharmaceuticals to buy it.
The correlation of Cipher Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cipher Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cipher Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Cipher Stock
Balance Sheet is a snapshot of the financial position of Cipher Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Cipher Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cipher Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cipher currently owns. An asset can also be divided into two categories, current and non-current.